#HVO hVIVO PLC – £11.5m RSV contract and notice of trading update December 10, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed an £11.5 million contract with an existing top-tier global pharmaceutical client to test its antiviral candidate using hVIVO’s Respiratory Syncytial Virus (“RSV”) Human Challenge Study Model. The Phase 2a randomised, double-blinded placebo-controlled human challenge trial will evaluate the safety, pharmacokinetics and antiviral activity of…

#HVO hVIVO PLC – Positive results from RSV human challenge trial October 7, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Enanta Pharmaceuticals (“Enanta”), reporting positive topline results from a Phase 2a Respiratory Syncytial Virus (“RSV”) human challenge trial (“HCT”) in healthy adults conducted by hVIVO for EDP-323, its second RSV antiviral candidate. EDP-323, a novel, oral, direct-acting antiviral in development for RSV infection, has…

#POLB Poolbeg Pharma PLC – RSV AI Drug Candidate Analysis Update December 20, 2023 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces the positive outputs from the lab-based analysis and successful prioritisation of the Respiratory Syncytial Virus (‘RSV’) drug targets and treatments identified as part of its artificial intelligence (‘AI’) led programme. Poolbeg’s team of scientific experts have reviewed the comprehensive data package obtained from this lab-based…

#HVO hVIVO PLC – £16.8m RSV contract & Trading ahead of guidance December 13, 2023 – Posted in: Blog, hVIVO (HVO)

£16.8m full-service RSV contract with top five global pharma client Highlights · Pharma client is funding expedited manufacture of additional supply of RSV challenge agent · Confirmatory challenge cohort to verify infectivity of the new RSV challenge virus batch · Multiple cohort challenge trial to test efficacy of client’s RSV antiviral candidate · Trading ahead of previous market expectations driven by margin expansion hVIVO plc (AIM & Euronext: HVO), the world leader in testing…

#HVO hVIVO PLC – £6.8m RSV human challenge contract signed February 6, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £6.8m contract with a leading pharmaceutical company based in Asia Pacific (“APAC”), to test its respiratory syncytial virus (“RSV”) antiviral drug candidate, using the hVIVO RSV Human Challenge Study Model. The Phase 2a double-blinded placebo-controlled…

#POLB Poolbeg Pharma PLC – Poolbeg identifies novel RSV drug candidates December 21, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical company, announces that it has successfully identified potential new drug candidates from its Respiratory Syncytial Virus (‘RSV’) artificial intelligence (‘AI’) Programme with OneThree Biotech, Inc. Since initiating the collaboration in February 2022, Poolbeg’s scientific team has worked closely with OneThree to build a tailored AI approach that leverages Poolbeg’s unique RSV human challenge trial data in order to identify disease-relevant biological…

#POLB Poolbeg Pharma – Proposal to Purchase Shares from Distribution in Specie Shareholders April 11, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that a number of new investors (“New Investors”) have expressed interest in acquiring up to £1.6m of Poolbeg Pharma plc shares which are currently locked-up and held in trust by Croft Nominees Limited (“Croft”) as a result of the distribution in specie from Open Orphan plc (“Open Orphan”) on 18…

#POLB Poolbeg Pharma – POLB sign AI discovery deal with OneThree Biotech for first human challenge trial March 10, 2022 – Posted in: Poolbeg Pharma (POLB)

POLB’s CEO Jeremy Skillington & One Three Biotech‘s co-founder & COO Brad Pryde catch up with @proactive_UK to discuss the recent AI deal to identify new drugs & treatments for RSV.

Open Orphan #ORPH – £5.1m RSV Human Challenge Study Contract Win November 17, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO , a subsidiary of Open Orphan, has signed a £5.1m contract with a biopharmaceutical company to test its Investigational Medicinal Product (IMP) using hVIVO’s respiratory syncytial virus (RSV) Human Challenge Study Model. The study is due to commence in H2 2022, with the revenue from the…

Open Orphan #ORPH – New hVIVO contract signed with a European Biotech Company to provide RSV human challenge study March 6, 2020 – Posted in: Open Orphan (ORPH)

6 March 2020: Open Orphan plc (ORPH) the rapidly growing CRO specialist pharmaceutical services Group which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce the signing of a new contract with a European Biotech Company for the provision of a RSV human challenge study. The study is projected to deliver £3.2m in revenue all of which is expected to be recognised in…